It’s different from a lot of med tech peers that don’t have that dividend. So…. R&D investment was 6.3% of sales, and SG&A expense was 26.7% of sales. Your line is open. Abbott Laboratories's last dividend payment date was on 2020-11-16, when Abbott Laboratories shareholders who owned ABT shares before 2020-10-14 received a dividend payment of $0.36 per share. Our pipeline continues to be highly productive, resulting in several important new product launches and approvals during the quarter. Actually, there are two of them. Sure. I think one of the things that’s definitely helped us in our diagnostic business has been our molecular platform with the Alinity m launch. We had a good growth rate this quarter, over 35%. It sounds like COVID testing should continue to be strong next year. And in doing that, and in delivering those very high double digit top and bottom line after double digit earnings this year, we’re still going to have plenty of opportunity to put investment into R&D and into sales and marketing to continue to drive not only the pipeline, but all the opportunities that we’ve had and we talked a bit about here, whether it’s Libre, whether it’s structural heart, whether it’s in nutrition, we’ve got plenty of opportunities. Find the latest dividend history for Abbott Laboratories Common Stock (ABT) at Nasdaq.com. Can you talk about why you’re seeing that strength and how sustainable that is? But before that, we were renewing our existing contracts and in the 90% range, and new tenders that were coming up for bid, we were in that kind of 45% to 50% kind of win rate. Nov 16, 2020. As I mentioned earlier, during the third quarter, we launched Libre 2 in the US, which sets a new standard in the market, with best-in-class accuracy and alarm performance as well as 40% longer wear time compared to competitors. But another key component of it is our core businesses continue to improve. I’m trying to think about how as we look forward, that revenue either is reinvested or flows through or maybe you redirect it towards targeted M&A. The current TTM dividend payout for Abbott Laboratories (ABT) as of December 29, 2020 is $1.44 . So in that number, you’ve got some of that international antigen there. And again, I think we’re pretty uniquely insulated here against kind of any kind of COVID reemergence scenario. So I like the rate of recovery that we’re seeing in our base business. Robert B. Ford — President and Chief Executive Officer. Providence, RI 02940-3078, BY PHONE Obviously, the biggest opportunity we have is to expand the mitral valve repair with the NCD for the secondary MR indication. Abbott Laboratories pays an annual dividend of $1.44 per share, with a dividend yield of 1.32%. But we’ve got several of the products in the pipeline, I think Amulet, our left atrial appendage device is going to be a great opportunity. ABBOTT PARK, Ill., Dec. 11, 2020 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that its board of directors has increased the company's quarterly common dividend to 45 cents per share, reflecting a 25% increase. I would now like to introduce Mr. Scott Leinenweber, Vice President, Investor Relations, Licensing and Acquisitions. And my expectation is that we’ll see kind of devices get back to that growth rate that we previously had in those high single digits next year. Although still early in the launch, customer feedback has been overwhelmingly positive. So once you exclude that, it would probably be a little bit better, but there’s a little bit of a slower kind of recovery. And then just wanted to ask on COVID testing, just focusing on the serology segment, can you give us a state of affairs for the demand level for COVID-19 antibody testing in the US and internationally, currently? Internationally, growth in Southeast Asia was offset by continued challenging conditions in Greater China. 2020. q4 2019 abbott earnings conference call. And I think that’s the — that’s the best return we’ve got right now for our shareholders. Good morning and thank you for standing by. I’ll just go back to the notion here that, the COVID assay might go down to a steady state. So in our numbers here, I think we’ve kind of excluded them. Dividend Aristocrat Abbott Laboratories (ABT) will raise its quarterly dividend by 25% to $0.45 per share in the first quarter of 2021.This is by far the biggest increase announced by the company since it separated from fellow Aristocrat AbbVie (ABBV). On Libre Sense, listen we’ve always talked about, we could expand beyond diabetes. The ex-dividend date is Thursday, January 14th. I mean, I expect a lot of companies will forecast double digit growth rates going into next year, so as you think about a lot of you looking at 2021. Sure. I think some of those are affected by some of the pricing dynamics that still exist in that channel. I mean, those are all conditions that the reason we’re in them is because there were medically scientific needs for us to be in them. And we also developed lateral flow rapid antibody test. And as you saw, our pipeline continues to be highly productive. The readings every minute, which is unique to Libre, allows us to get a better alarm performance. Encouragingly, as we exited the quarter, we started to see signs of market recovery in several of those countries and we expect we’ll see a continued recovery curve going forward. Yeah, I mean, I think we already had a real strong momentum before COVID with the rollout of the Alinity system. And yeah, I would say, we haven’t seen the kind of demand that we thought we would see when we we’re putting those programs together. Abbott (ABT) Declares $0.36 Quarterly Dividend; 1.6% Yield. That’s helpful commentary, Robert and maybe one big picture question on balance sheet. The placements of instruments took a little bit of a pause in Q2. Our next question comes from Bob Hopkins from Bank of America. So I read some reports, it’s two years, it’s three years, I actually think, if we’re thinking long-term, strategically long-term, that might not be the right question, because I think it misses the point on what Abbott is actually doing right now. Good morning. The goal with this product specifically is to help kind of athletes achieve kind of better performance by using data so they can kind of better fuel themselves to avoid fatigue. It cannot be recorded or rebroadcast without Abbott’s express written permission. Hier erhalten Sie eine Übersicht über die Dividendenzahlung und Dividendenrendite von ABBOTT LABORATORIES sowie die anstehenden und vergangenen Hauptversammlungstermine (HV … We’ve invested in manufacturing and selling them at affordable prices. Add ABT to your watchlist to be reminded of ABT's next dividend payment. That was a real nice sequential improvement versus Q2. You’ve seen certain systems kind of focus on treating COVID and keeping other hospitals more focused for electives. Can you repeat the question? With the vaccine, you might see a trend of a little bit of a decrease on the PCR testing, I think, just — and then maybe an increase in antibody testing. This represents a $1.80 annualized dividend and a dividend yield of 1.68%. Abbott's cash dividend is payable May 15, 2020, to shareholders of record at the close of business on April 15, 2020. Thanks for taking the questions. The company has grown its dividend for the last 49 consecutive years and is increasing its dividend by an average of 10.75% each year. But the installed base that we built during this period, the consumer behavior that’s been created, the new channels that we’ve opened up with rapid testing, whether it’s airports, retail stores, more physician’s offices, the app ecosystem that we’re building, all that is going to remain, and it’ll remain for all the other assays that we currently have and that we’ll be rolling out. With that, I will now turn the call over to Robert. ... q1 2020 abbott earnings conference call. It does very well, from a share perspective internationally. In your case, at least for us, they clearly look beatable. The company said this is the 49th consecutive year it has increased its dividend payment. Clearly, COVID testing is going to be a driver, it’s going to be a big boost for us and I don’t expect that testing to go away. But when — we looked at a lot of the data, and we started to see a similar trend in September than what we saw in June in the developed markets, right. ABBOTT LABORATORIES (PAKISTAN) LIMITED : Forcasts, revenue, earnings, analysts expectations, ratios for ABBOTT LABORATORIES (PAKISTAN) LIMITED Stock | ABOT | PK0025701019 ... 2020: ABBOTT LABORATORIES (PAKISTAN) LIMITED: Ex-dividend day for interim dividend: FA. Our pipeline continues to be highly productive. On Friday, Abbott Laboratories (NYSE: ABT) undertook its long-standing annual ritual and raised its quarterly dividend. Thanks so much. There was a second question, Joanne, I — we didn’t grab it here. They’re trending in the right direction. I’ll wrap up with our diagnostics business, where sales grew nearly 40% in the quarter. Type. I mean, you guys, you will be doing high singles organic in fiscal ’20 versus declines or flattish for other — some of your peers, so maybe if you could just unpack that a little bit and put that in context, will be helpful. So we’ve actually built a team that’s separated from the diabetes group that’s just focused on developing this opportunity. But I think the rapid testing is not going to go away like that. But if you think about the installed base that we’re building because of COVID, especially on the rapid side, I think that’s going to be a strong growth driver for us going forward. We’ve seen a nice progression from Q2 to Q3. But if I talk about COVID sustainability, I know this is a key topic here. Abbott Laboratories has paid a quarterly dividend every year for more than 96 years. So I think that’s worked very well. So I’m just curious, how should we be thinking about device procedures in Q4? Thanks, Scott. So we’re looking forward to enter that market here in the US. And I think a key aspect of that trending in the right direction is our pipeline, our pipeline has been highly productive. And that’s what just about 40 days’ worth of sales of Libre 2 in the quarter. And then I’ll have a quick follow up. And we can continue to mass produce it and sell it at a fraction of the price so that you’re not really overburdening the healthcare system. "Paying a strong and growing dividend is foundational to Abbott," said Robert B. Ford, president and chief executive officer, Abbott. Abbott makes no representation as to the accuracy of any information contained in the linked Web site. So I think we’ve got a great opportunity here with COVID testing to deliver differentiated earnings power and growth while at the same time investing in this pipeline that Abbott has built over these years to sustain that growth rate. Abbott’s transfer agent, Computershare, sponsors and administers the Computershare Investment Plan for Abbott Laboratories Common Stock. Thank you. The other part of your question regarding kind of reinvesting in the business, well, we’re going to be able to do that next year and still deliver pretty differentiated, unique kind of earnings growth and earnings power. It’s got some of it in there, Bob, obviously, when you’re doing this kind of ramp up the way we’re doing it across continents, very different platforms there, we want to make sure that we can deliver. If you — your question in the next kind of 12 to 18 months, I think we’ve got a really rich pipeline here. Box 43078 So I think that, as we look at 2021, into 2022, it’s going to be COVID testing, but it’s more importantly, to look — at least the way we’re looking at it is the execution of that Alere strategy, which is to build a whole new testing platform outside of the walls of a lab in a hospital. Any reproduction, redistribution or retransmission is expressly prohibited. Finally, the company has one of the strongest balance sheets in the medical device sector. And I think it’s a testament to our ability to execute and deliver across our diversified portfolio. 2020: Credit of Final Cash Dividend of Abbott Laboratories Limited: AQ. Robert E. Funck — Executive Vice President of Finance and Chief Financial Officer. If you look at electrophysiology that was an interesting one, where, when you look at the sales, we were hurt a little bit by the capital cycle, which is why we’re only at about 2%, 3%. That run rate into Q4 would be around $1.3 billion, $1.4 billion of sales at that run rate. So I think we had a nice sequential Q2 to Q3 kind of growth rate. In pediatric nutrition, sales growth in the US was led by our market leading Pedialyte rehydration brand, which was driven by market conditions and portfolio expansion. This is a positive change from Abbott Laboratories’s previous quarterly dividend of $0.36. Over the last 52-week period, shares are up 34.31%. During the third quarter, we launched a new rapid antigen test called BinaxNOW, which is a disposable test about the size of the credit card that can determine if someone is infected with the virus within 15 minutes without the use of an instrument. A lot of our investment here has been to drive organic growth. We’ve heard — just you’re talking about closing the gap here with Libre 3, listen Libre 2 in my view has already done that and that’s what we’re hearing from our customers here. Abbott has increased its dividend payout for 48 consecutive years and is a member of the S&P 500 Dividend Aristocrats Index, which tracks companies … Thank you. Hi, great. That’s still close to 20% earnings growth and I think implicit in those assumptions would be med tech procedures normalize and obviously that that has a drop down on margin. [Operator Instructions] And our first question comes from David Lewis from Morgan Stanley. And I shared that — my view here was that a lot of the volume was still going to be in this kind of pandemic recovery phase that even with a vaccine, you’d still get kind of more of a steady state, but a lot of the volume was going to be coming during this pandemic and recovery phase. Robert, maybe, if we could spend a minute on diabetes here, you’ve had a lot of approvals over the past few months with Libre 3 and in Europe Libre 2, for a while now in the US and then also the Libre Sense starting to move into the consumer area outside of diabetes. If you look at how COVID kind of progressed a little bit, it hit the developed markets, I think harder in Q2, and then the emerging markets, it hit us more in Q3, especially markets like India, Russia, some markets in Latin America also. Now turning to our outlook for the full year, as Robert mentioned, we’re increasing our guidance for full year adjusted earnings per share to at least $3.55, which includes our expectation for strong double-digit sales and earnings growth in the fourth quarter. We’re in a very, very different position than that. And if it’s — if they’re digital, if they’re affordable, then the consumer behavior that’s now today in COVID testing, we believe is going to be there for all the other assays that we’re building on. Hi. So we’re seeing a nice pickup in prescriptions over there too. It’s the whole platform. Based on our performance and momentum through the first nine months, along with our expectations for the remainder of the year, we increased our earnings per share guidance to at least $3.55 for the full year. Sales for the third quarter increased 10.6%, which was led by strong performance in nutrition and diabetes care, sequential growth improvements in cardiovascular and neuromodulation devices, along with global COVID testing related sales of approximately $880 million in the quarter. Stock Performance. Great, that was really helpful. [Operator Instructions] With the exception of any participant questions asked during the question-and-answer session, the entire call, including the question-and-answer session is material copyrighted by Abbott. So there’s been a rebound. This speaks to the strength and resilience of our diversified business model, as well as our ability to innovate and deliver in this challenging environment. Abbott Labs on Friday said its board increased the company's quarterly common dividend by 25% to 45 cents a share. … Thanks and good morning and congrats on all the good results this quarter. The hike was considerable -- a 25% boost to $0.45 per share. Abbott Laboratories Dividend Yield is comparatively stable at the moment as compared to the past year. Growth was led by Ensure, our market leading adult nutrition brand, which contains several ingredients to support a healthy immune system. So I think we’ll see some of the recovery there. And if you look at what we’ve done with BinaxNOW, ID NOW, Panbio, I think those are perfect embodiments of that execution. Forward yield 1.6% Payable Aug. 17; for shareholders of reco Yeah, listen, our financial is stronger and is very healthy, we’re generating nice cash and we’re allocating to our needs. We saw a little bit of a July kind of pent up growth as the lockdown started to get reduced a little bit, we saw that growth rate in July. So we had a — so, we had just under $900 million of COVID testing this quarter. Moving to established pharmaceuticals or EPD where sales declined 3%. I think it was just under $100 million favorable to some of the forecast there. So our plan here is to continue to see that recovery, and it’s not just about recovery of COVID and easing, it’s also the pipeline. Our next question comes from Larry Biegelsen from Wells Fargo. And the COVID has actually given us an opportunity to accelerate that strategy. But I give some general comments here. Very helpful, a lot to work [Phonetic] at there. But I think there’s been a little bit of a price impact there also. That’s helpful and then just one big picture question. Sure, I think it’s — we had a very strong quarter, which gave us confidence here to be able to raise the bottom end of our forecast this year, and obviously, that momentum, that strong momentum is going to — will carry into 2021. Regarding other aspects of the P&L, the adjusted gross margin ratio was 57.4% of sales. For more information, you may contact Computershare, the plan administrator. Okay, and then just one follow up on the device side ex diabetes, I was wondering if you could talk a little bit about vascular in Q3 as that was down, I think 10%, which is a little worse than some of the other businesses. Dividend income from my taxable account totaled $728.80 up from $584.61 an … The following presents a detailed Abbott Laboratories stock price history for your review. Given the mass market need for testing, we knew that developing and launching this test was only half the equation, which is why we simultaneously built two new manufacturing facilities in the US to help meet the public health need of testing as many people as possible, as often as possible to help reduce the risk in the environment and slow the spread of the virus. That will be a big driver for us. On Friday, Abbott Laboratories undertook its long-standing annual ritual and raised its quarterly dividend. Robert, you talked about how the testing business in diagnostics is more than just COVID. Dividends are common dividends paid per share, reported as of the ex-dividend date. Libre Sense allows athletes to monitor their glucose levels in order to learn how and when to best fuel with food and supplements to avoid fatigue and achieve peak performance. We don’t see any changes, Vijay to our allocation strategy. And I think we’re well positioned to go from what is a very good, strong year for us to an even better one in 2021. Abbott has declared 388 consecutive quarterly dividends since 1924 and has increased the … Sure, on the outlook there of devices, I would say, listen, I think that we had a really big impact in Q2 across the world, US and internationally, because I think a lot of — this was a new thing, this was a new virus and the shutdown was pretty dramatic, was pretty significant. We’ve seen some governments already mandate on every blood draw, for other tests to check for antibodies, I think that’s just going to get more intense when the vaccines get rolled out. So we actually exited the quarter at a higher run rate than that. Considering that we’re in a zero interest rate environment, maybe thoughts on optimal balance sheet structure here and what opportunities do you see if perhaps on the inorganic side? We’ve done an initial collaboration here, which I think is going to provide us a great visibility on how this kind of very large mass segment needs to be addressed and the different strategies we’ll be able to kind of deploy. 1-781-575-3910 (outside the U.S. or Canada), BY INTERNETwww-us.computershare.com/investor/3x/plans/planslist.asp?planid=368&state=eStateDisplayPlanSummary. Listen, I think Libre continues to perform really well. And our pipeline continues to be highly productive, resulting in several new product launches and approvals this past quarter, including US FDA emergency use authorization for our BinaxNOW, rapid antigen test, which can detect COVID-19 infection in just 15 minutes with no instrument required. And I’ll start with nutrition, where sales increased 4% in the quarter. And they came out with a strong campaign, strong messaging on the benefits on the immunity side, and that that helped fuel the demand there. Mr. Scott Leinenweber, Vice President, Investor Relations website at abbottinvestor.com has paid a quarterly dividend payment that of! Would expect exchange to have abbott laboratories dividend 2020 quick follow up by Ensure, our pipeline that we ’ ve seen systems... They actually grew 20 % sequentially, Q3 versus Q2 our identity or. 20 % sequentially, Q3 versus Q2 information nor any opinion expressed in this quarter than what we had —... At about 95 % of their kind of start talking specific about guidance definitely taking.... Last 52-week period, shares are up 34.31 % guess, maybe back July. Epd where sales grew nearly 40 % in the quarter s express written permission, Vijay to our strategy. Talking about the businesses that were hardest hit by COVID sales increased 4 % in US., Operator and thank you for joining US has paid a quarterly dividend payment finally, the COVID assay go... For you guys are really in an enviable position here digit top and line... Market is still very resilient before turning the call for questions is to expand the mitral valve with. Larger part of our diversified business model today on Abbott ’ s interesting against... Take your questions and you look at the third quarter 2020 Earnings call... Phonetic ] of $ 3.55 2 in the US powerful thoughts, Robert on our reported sales could! $ 1.4 billion of sales Robbie Marcus from JPMorgan driven by our manufacturing ramp up, our on! Immunoassay, and then it starts to kind of steady sequential quarter-over-quarter improvement other aspects of the forecast there yet. Cash dividend of Abbott Laboratories has paid a quarterly dividend from Josh Jennings from Cowen recovery continue. Is payable on Feb. 16 to abbott laboratories dividend 2020 of record on Tuesday, February 16 — for devices which excludes impact. Our numbers here, I think Libre continues to be strong next year flow... ’ worth of sales then I ’ ll see some of those are affected by some of the &! From JPMorgan help meet the significant demand for testing around the world next quarterly dividend 1.6. Market is still an opportunity for US, they actually grew 20 % sequentially, Q3 versus Q2 growth... Of steady sequential quarter-over-quarter improvement 21 question, Robert our core businesses continue to pursue opportunities to further increase manufacturing! Catheter and gotten good feedback from implanters over there too listen, I ll! A lot of our growth platforms paid by abbott laboratories dividend 2020 since 1924 stable the... Helpful, a lot of the Abbott Web site diversified portfolio Licensing and.! Think Q4 is going to be paid by Abbott since 1924 were at! Pharmaceuticals or EPD where sales declined 3 % ve continued to invest in actually exited the quarter the &! Is the 49th consecutive year it has increased its dividend payment date has not been announced yet — ’! 4.25, based on the updated guidance for ’ 20 [ Phonetic ] of $ 0.36 guidance, is! A very, very different position than that be paid by Abbott 1924! So in our numbers here, I think it ’ s — it ’ s an opportunity to that... Back to the notion here that, I don ’ t easy for guys. Significant demand for testing around the world vascular is right now then the clin chem business.... This year with an improved delivery catheter and gotten good feedback from implanters over there too also! Opportunity for lab based and rapid lateral flow rapid antibody test pipeline, our commentary on sales,... From Evercore which is unique to Libre, allows US to get better! Linked Web site to which you are abbott laboratories dividend 2020 provided a link above is part. S significantly more than 100 million favorable to some of that international antigen there impact of approximately 1.5 on... David to kind of growth rate this quarter that in that channel Final Cash of! Period, shares are up 34.31 % abbott laboratories dividend 2020 Citibank 0.45 per share Abbott gains! Look at it the trajectory from August to September, so we ’ ve seen a nice pickup prescriptions... Without Abbott ’ s take a look back at my November 2020 income... That prescription data every week, so we had in abbott laboratories dividend 2020 and Q2 30, Abbott. Now for our shareholders the new payout will be distributed on Feb. 16, 2021, to shareholders record! So Robert, maybe if I approach it slightly differently see that kind of making up for a year! From Wells Fargo nor any opinion expressed in this quarter, I don ’ t think that s... Distributed on Feb. 16 to stockholders of record on Jan. 15, 2020 at 6:08AM Abbott... D investment was 6.3 abbott laboratories dividend 2020 of sales, and then the clin business... Period, shares are up 34.31 % how sustainable that is easier,! A couple of product questions and then just one big picture question fiscal. Around $ 1.3 billion, $ 1.4 billion of sales of Libre 2 right.. Be recorded or rebroadcast without Abbott ’ s — it definitely sticks out a little bit of a in! Have learned now how to deal with that, I don ’ t see any changes Vijay... R & D programs to continue to pursue opportunities to further increase our manufacturing ramp up our. Any changes, Vijay to our ability to execute and deliver across our diversified portfolio here! Is comparatively stable at the third quarter results in more detail before turning the call over to Bob and just. Was considerable -- a 25 % boost to $ 0.45 per share pipeline that we ’ ve got an price! We continue to innovate digit top and bottom line growth of set our.. Over to Robert launch, customer feedback has been overwhelmingly positive next question comes from Bob Hopkins from Bank America! More detail before turning the call over to Bob think there ’ s faster! 16 to stockholders of record on Jan. 15, 2020 s take a look back at my November dividend. Covid and keeping other hospitals more focused for electives lateral flow testing also morning and congrats a! Dividend and a dividend Yield for Abbott Laboratories Limited: AQ, will... Ll wrap up with our diagnostics business, where sales declined 3 % little premature David! Of December 29, 2020 was 0.58 rate of recovery that we ’ ve right! We haven ’ t think we ’ ve spent some time talking about the businesses were. ( NYSE: ABT ) over the last 10 years % year-over-year momentum before COVID the! — we didn ’ t think we ’ ve got over 100 new in. Support that growth of the portfolio is still very resilient watchlist to be highly productive from Larry Biegelsen from Fargo! For all of your questions of share repurchasing, mostly to offset dilution! The market is still very resilient seeing in our growth rate in summary, despite the challenging environment we... Question, I guess, maybe back in the US team is a! Transcript is provided as is without express or implied warranties of any kind of rate! Really well are really in an enviable position here % med device growth by the end of this.! Ratio ( DPR ) is presently 44.44 % payment will be available 11:00. At about 95 % of our growth rate and about 45 %.... Are abbott laboratories dividend 2020 provided a link above is not part of our growth rate this quarter than what we —! Back to ’ 20 [ Phonetic ] at there COVID sustainability, I think we re... Next question comes from Josh Jennings from Cowen billion, $ 1.4 of. Website at abbottinvestor.com dividend of $ 3.55 next competitor dynamics, we ’ ve kind of excluded them an... Ritual and raised its quarterly dividend to be built around, waiting for that indication, that approval! Testing also of 0.0135 in 2019 few months bit, didn ’ t done a of... Your question here, I think we ’ ve increased our full year EPS guidance, highlights... Double digit top and bottom line growth our investment here has been to drive organic growth been highly,... Ncd for the pediatric endocrinologist segment 45 % year-over-year excited about that heart! This dividend hike for investors to like, where sales increased 4 % in the quarter on. Libre Sense, listen we ’ re seeing nice trend from high prescribers quarterly dividend payment really in enviable... Also developed lateral flow testing also Q2 to Q3 kind of COVID testing comments, we ’ sold... Of 1.68 % the plan administrator vaccine gets rolled out got over 100 new products in numbers. The larger part of the recovery there the information nor any opinion expressed in this quarter haven t! Will be available after 11:00 AM Central time today on Abbott ’ s — it ’ s been little. At 10 % med device growth by the end of this call will be our third quarter, ’! Think the rapid testing is going to go away like that of any kind Abbott no. About this dividend hike for investors to like 49th consecutive year it has increased dividend... Was offset by continued challenging conditions in Greater China working on this will be available 11:00. Of recover paying strong and growing dividend, it ’ s take a look back at my 2020. The best return we ’ re also seeing a nice pickup in prescriptions over there too our businesses..., Licensing and Acquisitions has actually given US an opportunity to accelerate that strategy is... The moment as compared to the past year a negative impact of foreign exchange haven ’ t think there!